Fund tied to Korro Bio (KRRO) director awarded stock and pre-funded warrants

Rhea-AI Filing Summary

Korro Bio, Inc. reported that investment entities associated with director and 10% owner Ali Behbahani acquired additional securities. On March 10, 2026, NEA 17 received 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at $0.001 per share, subject to a 9.99% ownership cap that can be raised up to 19.99% with 61 days’ notice. The same day, NEA 17 was also awarded 207,100 shares of Common Stock at $11.11 per share, bringing its indirectly held Common Stock position to 1,297,893 shares. Behbahani is a manager of the NEA 17 general partners and disclaims beneficial ownership of portions in which he has no pecuniary interest.

Insights

Equity capital markets analyst

Fund tied to a Korro Bio director increased its position via warrants and shares.

Entities related to Ali Behbahani acquired Pre-Funded Warrants and Common Stock directly from Korro Bio under a subscription agreement dated March 9, 2026. These are classified as grants or awards, not open-market purchases.

The 242,945 Pre-Funded Warrants carry a token $0.001 exercise price but include a Beneficial Ownership Limitation at 9.99%, adjustable up to 19.99% with 61 days’ notice. This clause governs how much can be exercised at any time.

Indirectly held Common Stock rose to 1,297,893 shares, but Behbahani disclaims beneficial ownership where he has no pecuniary interest. Overall, the transactions look like participation in a financing rather than a discretionary market bet, so their informational signal is modest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A(1)		207,100	A	$11.11	1,297,893	I	See Note 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		A(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	I	See Note 2(2)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did NEA 17 acquire in this Korro Bio (KRRO) Form 4?

Entities associated with Ali Behbahani acquired 242,945 Pre-Funded Warrants and 207,100 shares of Korro Bio Common Stock. Both were received from the issuer under a subscription agreement dated March 9, 2026, rather than through open-market purchases.

How many Korro Bio Pre-Funded Warrants were granted and on what terms?

The fund received 242,945 Pre-Funded Warrants, each exercisable into one Common Stock share at an exercise price of $0.001. These warrants are exercisable any time after issuance, subject to a Beneficial Ownership Limitation on post-exercise share ownership.

What is the Beneficial Ownership Limitation on Korro Bio’s Pre-Funded Warrants?

The warrants may not be exercised if doing so would cause the holder and affiliates to exceed 9.99% ownership of Korro Bio Common Stock. The holder can adjust this cap, with 61 days’ notice, up to but not exceeding 19.99%.

How many Korro Bio Common shares does the NEA 17 fund hold after these transactions?

Following the March 10, 2026 grant of 207,100 shares, the fund’s indirectly held Korro Bio Common Stock position is 1,297,893 shares. This reflects shares held via NEA 17, the direct beneficial owner of the reported securities.

Did Ali Behbahani personally buy or sell Korro Bio (KRRO) stock in this filing?

The filing shows acquisitions by NEA 17, a fund structure whose general partners include entities managed by Behbahani. He disclaims beneficial ownership of portions where he has no pecuniary interest, so the transactions are attributed primarily to the fund, not personal trading.

Were these Korro Bio transactions open-market trades or part of an agreement?

The securities were acquired from Korro Bio pursuant to a Subscription Agreement dated March 9, 2026. The transaction code “A” and footnotes classify them as grants or awards, rather than open-market buying or selling on an exchange.